Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?
Br J Cancer
.
2017 Jul 11;117(2):157-300.
doi: 10.1038/bjc.2017.176.
Epub 2017 Jun 22.
Authors
N LeVasseur
1
,
S K Chia
1
Affiliation
1
Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.
PMID:
28641309
PMCID:
PMC5520520
DOI:
10.1038/bjc.2017.176
No abstract available
Publication types
Editorial
Comment
MeSH terms
Breast
Breast Neoplasms*
Chemotherapy, Adjuvant
Docetaxel*
Epirubicin
Humans
Substances
Docetaxel
Epirubicin